Patents Assigned to NOVALIQ GmbH
  • Patent number: 10130707
    Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: November 20, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Publication number: 20180303849
    Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
    Type: Application
    Filed: June 25, 2018
    Publication date: October 25, 2018
    Applicant: NOVALIQ GMBH
    Inventors: Bastian THEISINGER, Sonja THEISINGER, Bernhard GÜNTHER
  • Patent number: 10064944
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: September 4, 2018
    Assignee: NOVALIQ GMBH
    Inventor: Clive G. Wilson
  • Patent number: 10058615
    Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 28, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Bastian Theisinger, Sonja Theisinger
  • Patent number: 10045996
    Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: August 14, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Publication number: 20180221485
    Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 9, 2018
    Applicant: NOVALIQ GMBH
    Inventors: Bastian THEISINGER, Sonja THEISINGER, Bernhard GüNTHER
  • Patent number: 9968678
    Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 15, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Publication number: 20180071229
    Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
    Type: Application
    Filed: September 21, 2017
    Publication date: March 15, 2018
    Applicant: NOVALIQ GMBH
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Publication number: 20180021434
    Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.
    Type: Application
    Filed: September 29, 2017
    Publication date: January 25, 2018
    Applicant: NOVALIQ GMBH
    Inventors: Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Publication number: 20180008710
    Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
    Type: Application
    Filed: July 24, 2017
    Publication date: January 11, 2018
    Applicant: NOVALIQ GMBH
    Inventors: Bastian THEISINGER, Sonja THEISINGER, Bernhard GÜNTHER
  • Patent number: 9770508
    Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: September 26, 2017
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew
  • Patent number: 9757459
    Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: September 12, 2017
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Patent number: 9757460
    Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: September 12, 2017
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer, Clive Wilson, Anthony Pettigrew, Annette Hüttig
  • Publication number: 20170216204
    Abstract: The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.
    Type: Application
    Filed: April 19, 2017
    Publication date: August 3, 2017
    Applicant: NOVALIQ GMBH
    Inventors: Bastian THEISINGER, Sonja THEISINGER, Bernhard GÜNTHER
  • Publication number: 20160101178
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Application
    Filed: December 17, 2015
    Publication date: April 14, 2016
    Applicant: NOVALIQ GMBH
    Inventor: Clive G. WILSON
  • Patent number: 9308262
    Abstract: The invention provides semi-solid or liquid pharmaceutical compositions for topical administration to a finger- or toenail of a human. The compositions are useful for the delivery of active ingredients deep into the nail. Various active ingredients may be incorporated, such as antifungal agents, anti-infectives, anti-inflammatory agents, immunosuppressants, local anesthetics, and retinoids.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: April 12, 2016
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Gunther, Bastian Theisinger, Sonja Theisinger
  • Patent number: 9241900
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: January 26, 2016
    Assignee: NOVALIQ GMBH
    Inventor: Clive G. Wilson
  • Publication number: 20150224064
    Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
    Type: Application
    Filed: September 12, 2013
    Publication date: August 13, 2015
    Applicant: Novaliq GmbH
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Patent number: 8986738
    Abstract: A medical aid for the direct transport of at least one drug into lung regions of a patient, wherein provided as the carrier for at least one active substance is at least one semifluorinated alkane in which the at least one active substance is purely physically dissolved in a homogeneous phase.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: March 24, 2015
    Assignee: NOVALIQ GmbH
    Inventor: Hasso Meinert
  • Patent number: 8796340
    Abstract: The invention provides novel pharmaceutical compositions comprising the active ingredient propofol. Preferably, propofol is dissolved in at least one semifluorinated alkane. The compositions, which are preferably liquid or gel-like, may optionally comprise further excipients. They may be used as fill material in capsules, as buccal or nasal sprays, or as aerosols for pulmonary administration. They are particularly useful for the transmucosal administration of propofol.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: August 5, 2014
    Assignee: Novaliq GmbH
    Inventors: Bastian Theisinger, Sonja Theisinger